最新发布
No, imaging won’t help farmers control plant disease
Kevin Fries is the lead agronomic modeler at InnerPlant, a California-based biotech company turning plants into living s…
UPL Expands Nature-Based Agriculture Portfolio with Investment in Japan’s PhytoChrome
11 September 2026, New Delhi: UPL Corp Japan has acquired a stake in PhytoChrome Co., Ltd., a Japanese company specializ…
P101 leads €5.2 Mn round in Biorsaf as Food RegTech consolidation accelerates
Italy’s food industry is becoming the next frontier for RegTech as Biorsaf raises €5.2 million in a round led by P101 SG…
Xinxiang Chemical Fibre’s RMB1.3 Bn bet on next generation of green fibres
Xinxiang Chemical Fibre Co., Ltd. is putting biomass at the centre of its next growth phase, with a proposed RMB1.3 bill…
Comunicação química abre caminho para ampliar controle biológico
Foto: Frank Peairs / Colorado State University – Bugwood Compostos químicos liberados por plantas, insetos e micro…
Bayer leva ciência agrícola a comunidades em turnê nos EUA
Foto: Bayer A Bayer iniciou nos Estados Unidos uma turnê nacional do projeto Science Delivers, com uma unidade móvel vol…
How Farmer Cooperatives Are Benefiting from Digital Technologies
2 For years, farmer cooperatives have helped smallholder farmers achieve something they could rarely achieve alone: buy …
Mercado Agrícola – 11.set.2026
O mercado de soja e milho recebe suporte da alta do petróleo e das dúvidas sobre o potencial produtivo das lavouras dos …
Allogenetics adds €3.8M for rejection-resistant donor lungs
Why it matters: Instead of suppressing the transplant recipient’s immune system for life, Allogenetics is trying to make the donated organ harder for that immune system to recognize. That could tackle one of lung transplantation’s biggest limitations. Five-year survival remains about 59%, while recipients typically require chronic immunosuppression that leaves them vulnerable to infections, malignancies and other complications.
Simris steps on Heidelberg Pharma’s toes with amanitin pivot
Why it matters: Amanitin, a deadly cyclic peptide toxin found in poisonous mushrooms like the death cap, is not new territory for Pahl. He spent years developing amanitin as a payload for antibody-drug conjugates (ADC) at Heidelberg Pharma, where it now forms the basis of the German biotech’s proprietary ATAC platform and its core business strategy.